NEJM Audio Summary - April 12, 2012

Excerpted Script

8'23"| "A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis", by B. Joseph Elmunzer, from University of Michigan Medical Center, Ann Arbor. This study involving 602 patients at increased risk for pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) evaluated the efficacy of prophylactic rectal indomethacin for the prevention of post-ERCP pancreatitis. The majority of patients (82%) had a clinical suspicion of sphincter of Oddi dysfunction. Post-ERCP pancreatitis developed in 9.2% patients in the indomethacin group and in 16.9% patients in the placebo group. Moderate-to-severe pancreatitis developed in 4.4% patients in the indomethacin group and in 8.8% patients in the placebo group. Among patients at high risk for post-ERCP pancreatitis, rectal indomethacin significantly reduced the incidence of the condition.

へー！！！　NNT計算すると、100 / (16.9 - 8.8) = 12.345679 って話。

参考

• 内科開業医のお勉強日記「ERCP膵炎：検査後直腸内インドメタシン投与でリスク低下」
• 呼吸器内科医「ERCP後膵炎の発症予防にインドメタシン直腸内投与が有効」